Recent Updates
Recently added Catalysts
CSTL Positive Sentiment

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

Key Takeaway: Castle Biosciences, a diagnostics company, will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The presentation will provide an overview of the company's innovative tests aimed at improving patient care. A live audio webcast will be available for those unable to attend in person.
Price reaction · baseline $34.74 (2025-11-10 close) · hit pre-market · clean, no other CSTL news in the window
day 0 close · peak
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Castle Biosciences is presenting at a notable healthcare conference.
  • The company focuses on innovative tests that improve patient care.
  • Live audio webcast allows broader access to the presentation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~33 mo
Low dilution risk
Lead asset
diacerein 1%
Phase 2 · Epidermolysis Bullosa

Full Press Release Details

FRIENDSWOOD, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 37thAnnual Healthcare Conference on Tuesday, Dec. 2, 2025, at 1:10 p.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website atir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.
About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visitwww.CastleBiosciences.comand connect with us onLinkedIn,Instagram,FacebookandX.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeqare trademarks of Castle Biosciences, Inc.

Investor Contact:Camilla Zuckeroczuckero@castlebiosciences.com

Source:Castle Biosciences Inc.

Frequently Asked Questions

When is Castle Biosciences presenting?

Castle Biosciences will present on December 2, 2025, at 1:10 p.m. ET.

How can I access the presentation?

The presentation will be available via a live audio webcast on their website.

What is the focus of Castle Biosciences?

The company focuses on innovative tests for dermatologic and gastroenterological diseases.

Where can I find more information about Castle Biosciences?

More information is available on their official website and social media platforms.

Last updated: Nov 11, 2025